Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies Corp is poised for significant financial growth, with anticipated increases in average selling prices (ASPs) for its clonoSEQ product projected to reach $1,700-$1,800 by 2029, as prices rise from $1,307/test at the end of 2025 following a strategic renegotiation with major health plans. The company is also witnessing a shift towards a greater mix of blood testing, which has improved over the past year, as well as a growing utilization rate in both community oncology settings and among patients, further driving testing volumes. Additionally, the adoption of the NovaSeq X technology is expected to enhance margins while incremental volume and ASP enhancements are forecasted to elevate gross profit significantly in the coming years.

Adaptive Biotechnologies Corp has revised its revenue guidance for minimal residual disease (MRD) significantly, projecting $8-9 million for 2026, down from $19.5 million in 2025, indicating potential challenges in achieving forecasted growth. The company anticipates a decline in clinical milestone payments by 56% year-over-year, despite expecting over 30% volume growth in its clonoSEQ test, which could suggest difficulties in sustaining revenue streams. Furthermore, the Immune Medicine segment is expected to generate flat revenue, reflecting a lack of growth drivers as Adaptive focuses on developing its TCR-Antigen model and autoimmunity programs, compounded by hurdles in patient uptake of MRD testing.